Literature DB >> 10770556

Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.

K Van Laethem, M Witvrouw, J Balzarini, J C Schmit, S Sprecher, P Hermans, M Leal, T Harrer, L Ruiz, B Clotet, M Van Ranst, J Desmyter, E De Clercq, A M Vandamme.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770556     DOI: 10.1097/00002030-200003100-00027

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  7 in total

1.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

2.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

3.  Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.

Authors:  Hauke Walter; Barbara Schmidt; Marianne Werwein; Eva Schwingel; Klaus Korn
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Abacavir: a review of its clinical potential in patients with HIV infection.

Authors:  P S Hervey; C M Perry
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 5.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

6.  Abacavir/lamivudine combination in the treatment of HIV: a review.

Authors:  Geetha Sivasubramanian; Emmanuel Frempong-Manso; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

7.  Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia.

Authors:  Nyoman Sri Budayanti; Tuti Parwati Merati; Budiman Bela; Gusti Ngurah Mahardika
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.